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The quantity of cells is widely accepted as the main factor inﬂuencing the outcome after umbilical cord blood
transplantation (UCBT) however, the quality of the cord blood units (CBUs) has been less studied. In order to
determine the impact of qualitative variables in UCBT outcomes, we conducted a multicenter retrospective
study in adult patients with hematological malignancies who underwent single UCBT after a common
myeloablative conditioning regimen. One hundred and ten patients from 3 institutions [median age, 35 years
(range 18-55)] were included. Quantitative (TNC and total CD34þcells) and qualitative variables [viable
CD45þ (vCD45þ), vCD34þ and clonogenic efﬁciency [(CLONE), quotient of post-thaw colony-forming units
(CFU)] and pre-freeze CD34þ cells predicted engraftment in univariate analysis however, only 2 qualitative
variables remained signiﬁcant in the multivariate analysis. Infusion of more than 2  107 post-thaw vCD45þ
cells per kilogram was signiﬁcantly associated with faster neutrophil (P ¼ .01), platelet engraftment (P ¼ .01),
higher disease-free (P ¼ .01) and overall survival (0.02). In addition, CLONE  20% predicted a faster
neutrophil (P ¼ .005), platelet engraftment (P ¼ .01) and contributed to decrease the non-relapse mortality
(P ¼ .02). Our study suggests that the vCD45þ cells dose and CLONE are powerful surrogate markers of graft
quality and can potentially help on CBUs selection if tested with representative reference samples.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
In addition to the level of HLA matching, total nucleated
cells (TNC) and CD34þ cells content are the most important
factors inﬂuencing engraftment after umbilical cord blood
transplantation (UCBT) [1-3]. In spite of well-deﬁned cellular
thresholds for cord blood unit (CBU) selection, engraftment
delay and graft failure still remain major concerns, suggest-
ing that other “qualitative” factors may also inﬂuence CBU
engraftment capacity. In this regard, there is evidence that
colony-forming unit (CFU) counts are associated with rateually to this work.
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ty for Blood and Marrow Transplantation.and kinetics of engraftment and also with long-term out-
comes, suggesting the role of functional assays in deter-
mining CBU quality [4,5].
Graft potency, deﬁned as the ability of the hematopoietic
progenitor cells (HPC) to engraft, is in general assessed by
viability of ﬂow cytometry and/or clonogenic assays. These
tests allow the enumeration of viable cells and infused CFU,
which are both associated with outcomes after UCBT [5];
however, clear deﬁnitive thresholds have not been estab-
lished. In addition, and based on the correlation between
CFU and CD34þ cells, we previously proposed the use of the
clonogenic efﬁciency (CLONE) as a new measure of HPC
potency [6]. Herein, we deﬁned the estimated CLONE
(ECLONE), measured as the ratio between post-thaw CFU
counts and prefreezing CD34þ cell numbers, that could
provide insight into the dynamics of the CD34þ function
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recovered post-thaw CFU are below the expected value for
the seeded prefreezing CD34þ cells, a loss of HPC function
may be anticipated.
In this study, we assessed quantitative CBU characteris-
tics (as conventional TNC and CD34þ cell counts) and
qualitative variables (viable CD45þ [vCD45þ], viable CD34þ
[vCD34þ], viable CD3þ [vCD3þ] cell counts, CFU, and
ECLONE). We hypothesized that qualitative variables may
impact outcomes after UCBT when the cell dose threshold is
achieved. To identify the qualitative factors affecting out-
comes after UCBT, we conducted a retrospective study of
adult patients with hematological malignancies who un-
derwent single UCBT.
METHODS
Enrollment Criteria
The study included 110 consecutive adult patients who received unre-
lated single UCBT in the Hospital Vall d’Hebrón, Sant Pau and Germans Trias
i Pujol (Barcelona) between January 2005 and December 2013. All patients
with hematological malignancies were eligible for enrollment if they met
the following criteria: (1) high-risk hematological malignancy requiring
urgent hematopoietic cell transplantation; (2) absence of suitable related or
unrelated donor (HLA identical or 1 antigen mismatched); (3) lack of suit-
able HLA-matched unrelated donor at a reasonable time after the start of the
search through international registries, and (4) a suitable umbilical CBU
available, as described below. Patients receiving ex vivoeexpanded grafts
were excluded. Patients gavewritten informed consent for their inclusion in
each transplantation protocol.
CBU Selection
The CBUs selected for transplantation should be 4/6 HLAematched
with the recipient (considering HLA-A and -B at antigen level and -DRB1 at
allele level). Cell dose was considered the most important criterion for unit
selection. Those units fulﬁlling HLA-matching criteria were ranked accord-
ing to their content of TNCs and CD34þ cells. Minimum cell doses required
were TNC >1.5  107/kg and CD34þcells >.6  105/kg.
Conditioning Regimen, Graft-versus-Host Disease Prophylaxis, and
Supportive Care
All patients received myeloablative conditioning. Two conditioning
protocols were used and were described previously [7-9]. In brief, 8 patients
received thiotepa (10 mg/kg), busulfan i.v (9.6 mg/kg), and cyclophospha-
mide (120 mg/m2), whereas the remaining 102 patients received the same
conditioning regimen but cyclophosphamide was replaced by ﬂudarabine
(150 mg/m2). All patients received in vivo T cell depletion with rabbit
antithymocyte globulin (Thymoglobulin, Genzyme, Lyon, France) at a total
dose, 6 mg/kg to 8 mg/kg.
Graft-versus-host disease (GVHD) prophylaxis included cyclosporine
(1.5 mg/kg/12 hours i.v) followed by 3 to 5 mg/kg/12 hours orally when oral
intake was possible and slow tapering starting between dayþ90 and þ 180,
if feasible. Cyclosporine was combined with a short-course of steroids
(1 mg/kg/daily) from day þ14 to þ28 or mycophenolate mofetil (15 mg/kg/
daily from -1 to þ30 day).
Granulocyte colonyestimulating factor was administered s.c at 5 mg/kg/
daily from dayþ7 until neutrophil engraftment. Antibacterial and antifungal
prophylaxis were given according to each center’s protocol.
Cord Blood Banks and Graft Characteristics
CBUs were thawed and washed according to the standard method of
Rubinstein et al. [10] or a modiﬁed approach using an automated system
[11]. Both international and domestic (Spanish) cord blood banks (CBBs)
provided CBUs for transplantation. Prefreezing information was obtained
from the original CBB provider. Post-thaw characteristics were determined
before infusion at Banc de Sang i Teixits cell therapy service, which served as
a processing laboratory for all referring transplantation units.
Laboratory Analysis
Automatic cell count
Counting of TNC, RBC, and platelets were performed on each sample by
using an automatic cell counter that detects and measures changes in
electrical resistance (impedance) when a particle in a conductive liquid
passes through the device (Coulter AcT diff, Beckman Coulter, Miami, FL).Flow cytometry
Post-thaw CD45þ and CD34þ cell enumeration, including viability, was
performed following the International Society of Hematology and Graft
Engineering protocol but with modiﬁed gating for better determination of
viable cells, similar to the method applied by Scaradavou et al. [12]. This
methodology excludes only erythroblasts and debris to evaluate the
number of live and dead cells. All cellular events present were thus
counted and therefore, proportions of dead and live cells were more pre-
cisely calculated.
Samples were taken after washing and incubated for 15 minutes at 4C
in the dark with antihuman phycoerythrin (PE)elabeled monoclonal anti-
bodies (mAbs) against CD34þand CD3þ combined with FITC-labeled CD45þ
at a saturating concentration. After incubation, the samples were lysed in
ammonium chloride for 10 minutes and a volume of commercially available
ﬂuorescent mycrobeads were added and gently mixed as an internal stan-
dard before acquisition, according to the manufacturer’s instructions (Per-
fect Count; Cytognos, Salamanca, Spain) to evaluate their absolute count
using cytometric single-platform analysis [13]. The samples were also
incubated with 7-aminoactinomycin D for 5 minutes to determine the cell
viability/permeability. The cell subsets were then analyzed by their ﬂuo-
rescence proﬁle and forward and side-scatter characteristics, on a Becton-
Dickinson FACScalibur ﬂow cytometer with the BD software, Cellquest
(Becton-Dickinson, Franklin Lakes, NJ).
Clonogenic assays
Progenitor cell assays were performed after thawing and washing with
methylcellulose-based H4434 medium. In detail, the cells were seeded
directly onto methylcellulose, mixed gently and then plated onto petri
dishes and incubated at 37C in a humidiﬁed atmosphere of 5% CO2 in air.
Granulocyte macrophage colonyeforming units, burst-forming units-
erythroid, and CFU-mix colonies were identiﬁed and counted using standard
criteria after 10 days in culture [14]. For CFU counting, only colonies with
over 50 cells were enumerated. Total CFU, deﬁned as the total count of
colonies, regardless of their lineage, was used for analyzing the clonogenic
potential of the product.
Deﬁnitions
Variables for CBU speciﬁcations
Quantitative variables considered for the study were prefreezing TNC
and CD34þ cells and post-thaw TNC enumerated at the processing labora-
tory. Qualitative variables considered for the study were post-thaw 7-
aminoactinomycin D cells counts (infused vCD45þ, vCD34þ, and vCD3þ),
CFU, and ECLONE. The latter was calculated using the ratio between post-
thaw CFU (obtained in the processing laboratory) and prefreezing
CD34þcells (reported by the CBB of origin). Provided that CFU and CD34þ
have a statistically signiﬁcant correlation in standard conditions [6,15] for a
given prefreeze CD34þ count, a post-thaw CFU value is expected. Decrease of
ECLONE below that which is expected could be a surrogate of loss of graft
potency.
Donor engraftment
Myeloid engraftment was deﬁned as the ﬁrst of 3 consecutive days with
an absolute neutrophil count equal or higher to .5  109/L and transfusion-
independent platelet engraftment was deﬁned as the ﬁrst of 3 consecutive
days with 20  109/L without transfusion support for 7 consecutive days.
Sustained donor engraftment was deﬁned as sustained donor derived count
recovery with full donor chimerism (>95% donor hematopoiesis). Full donor
chimerism was determined by quantitative polymerase chain reaction of
informative polymorphic short tandem repeat regions of DNA from donor
and recipient using AmpFlSTR Identiﬁler PlusPCR Ampliﬁcation kit (Applied
Biosystems, Carlsbad, CA). Patients who survived >42 days after trans-
plantation and who failed to achieve myeloid engraftment were considered
to have primary graft failure. Secondary graft failurewas deﬁned as the loss of
the engraftment in the absence of relapse.
GVHD, nonrelapse mortality, relapse, disease-free survival, and overall
survival
GVHD was deﬁned and graded according to standard criteria [16,17].
Patients dying before þ100 day were not considered for chronic GVHD
analysis. Nonrelapse mortality (NRM) was deﬁned as death from any cause
without evidence of relapse. Disease-free survival (DFS) was deﬁned as sur-
vival from the time of transplantation without evidence of disease relapse/
progression. Overall survival (OS) was deﬁned as survival from the time of
transplantation.
Baseline Disease Status
Disease status at the time of transplantation was classiﬁed as follows:
(1) early phase: acute leukemia, myelodysplastic syndrome (MDS) or
Table 1
Patient and Transplantation Characteristics
Characteristics (N ¼ 110) No. of Patients (%)*
Age, median (range, IQR), yr 35 (18-55, 26-46)
Year of transplantation
2005-2009 46 (42)
2010-2013 64 (58)
Sex
Female 56 (51)
Male 54 (49)
Recipient’s body weight, median,
(range, IQR), kg
70 (40-113, 60-77)
CMV serologic status
Positive 77 (70)
Negative 33 (30)
Diagnosis
AML 55 (50)
ALL 26 (24)
Lymphoma (non-Hodgkin and Hodgkin) 17 (16)
CML 6 (5)
Other 6 (5)
Disease status
Early 51 (46)
Intermediate 28 (25)
Advanced 31 (28)
Previous autologous transplantation
Yes 20 (18)
No 90 (82)
GVHD prophylaxis
CsA-PDN 78 (71)
CsA-MMF 32 (29)
Conditioning regimen
TT þ FLU þ BU þ ATG 102 (93)
TT þ CY þ BU þ ATG 8 (7)
HLA compatibilityy
4 out of 6 71 (65)
5 out of 6 32 (29)
6 out of 6 7 (6)
ABO blood group incompatibility
Major 24 (22)
Minor 27 (24)
None 59 (54)
Donor-recipient sex match, no. (%)
Male-male 34 (31)
Male-female 25 (23)
Female-male 23 (21)
Female-female 28 (25)
IQR indicates interquartile range; AML, acute myeloid leukemia; ALL,
acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CsA,
cysclosporine; PDN, prednisone; MMF, mycophenolate mofetil; TT, thio-
tepa; FLU, ﬂudarabine; BU, busulfan; ATG, antithymocyte globulin; CY,
cyclophosphamide.
* Percentatges may not add to 100 because of rounding.
y By considering HLA-A and -B at antigen level and -DRB1 at allele level.
Table 2
Cell Content of the Cord Blood Units
Cell Median (Range, IQR)
At time of freezing
TNCs  107 per kg 3 (1.5-6.7, 2.28-3.85)
CD34þ cells  105 per kg 1.73 (.6-9.2, 1.24-3.12)
At time of infusion
TNCs  107 per kg 2.6 (1-5.3, 2.02-3.2)
Viable CD45þ  107 per kg 2.4 (.5-4.8, 1.7-3)
Viable CD34þ cells  105 per kg 1 (.2-4.2, 0.67-1.84)
Viable CD3þ cells  107 per kg 4.1 (.8-38, 2.6-6.2)
CFU  104 per kg 3.7 (.1-16, 2.04-6.65)
ECLONE, (%) 22 (.6-64, 11.3-36.2)
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or chronic myeloid leukemia (CML) in the ﬁrst chronic phase; (2) interme-
diate phase: acute leukemia, lymphoma or MDS in a second remission, and
CML in a second or further chronic or accelerated phase; and (3) advanced
phase: acute leukemia and lymphoma not in remission, CML in blast crisis,
and untreated refractory anemia with excess blasts [18].
Statistical Analysis
Clinical, demographic, and graft potency variables considered for
prognostic factors analysis were year of transplantation, gender, age, disease
status at transplantation, diagnosis, recipient cytomegalovirus (CMV)
serology, patient’s body weight, HLA match, GVHD prophylaxis, ABO blood
group compatibility, prefreezing TNCs, prefreezing total CD34þ cells, post-
thaw TNCs, post-thaw vCD45þ cells, post-thaw vCD34þ cells, post-thaw
vCD3þ, CFUs, and ECLONE. Continuous variables were dichotomized at the
most discriminative cut-off for each outcome. Baseline characteristics were
described as median and interquartile range for quantitative variables and
frequency and percentages for categorical variables. Correlation between
variables was analyzed by Spearman’s correlation test. Cumulative inci-
dence curves were used in a competing risk setting to calculate the cumu-
lative incidence of neutrophil and platelet engraftment, NRM, and relapse
[19]. Death without engraftment was the competing event for neutrophil
and platelet engraftment. Relapse was considered the competing event for
NRM. Death without relapse was the competing event for relapse. Unad-
justed time to event analysis were performed by Kaplan-Maier estimate and
for comparisons, the log-rank test was used [20]. Characteristics selected for
inclusion in multivariate model were established at P < .10 in univariate
analysis. Cox proportional hazard regression method and Fine and Gray
method for competing events were used for multivariate analysis [21]. Only
cases with complete data (n ¼ 105) were considered in multivariate model.
Two-sided P values < .05 were considered statistically signiﬁcant in the
multivariate model. Statistical analysis was conducted using the SPSS sta-
tistical software (SPSS version 20.0, Chicago, IL) and R version 2.15.2 (The
CRAN project) with packages survival v2.37-7, cmprsk v2.2-7, splines v3.1.7
and prodlim v1.4.5.
RESULTS
Patient, Graft, and Transplantation Characteristics
Table 1 shows the main characteristics of the 110 patients
included in the study. Median age was 35 years (range, 18 to
55), 81 patients (74%) had acute leukemia, 51 (46%) received
transplantation in the early phase of the disease, and 71
(65%) received CBUs mismatched at 2 loci.
Cell Doses and Potency Factors of the Umbilical CBU
Table 2 summarizes cell dose and qualitative character-
istics contained in CBU prefreezing and at the time of infu-
sion (post-thaw). The R correlation coefﬁcient of post-thaw
vCD45þ and prefreezing TNC was .59 (P < .01) and correla-
tion of post-thaw vCD34þ and prefreezing total CD34þ cell
numbers was .73 (P < .01). Interestingly, ECLONE showed a
very high linear correlation (R ¼ .082, P < .01).
Factors Predictive of Outcome
Results of multivariate analyses are summarized in
Table 3. The data from univariate analysis are presented in
Supplementary Material.
Neutrophil engraftment
Nine patients (8%) died before day 42 after trans-
plantation without engraftment (median time, 15 days;
range, 8 to 38) and were considered not evaluable for
engraftment. Eleven of 101 patients (11%) had primary graft
failure and the remaining 90 patients (82%) achieved
neutrophil engraftment at a median of 23 days (range, 8 to
50). The cumulative incidence of neutrophil engraftment at
day 28, 42, and 60 after transplantation was 57% (95% con-
ﬁdence interval [CI], 48% to 67%), 75% (95% CI, 67% to 84%),
and 82% (95% CI, 76% to 90%). Multivariate analysis indicated
that higher post-thaw vCD45þ cells (P ¼ .01), higher post-
thaw vCD34þ cells (P ¼ .01), higher ECLONE (P ¼ .005), andrecipient CMV negative status (P ¼ .02) were independently
associated with higher cumulative incidence of engraftment.
Figures 1A and 1B show the effect of post-thaw vCD45þ cell
dose and ECLONE on neutrophil engraftment in univariate
Table 3
Factors Affecting the Outcome after UCBT in Multivariate Analysis
Variables HR 95% CI P Value
Neutrophil engraftment
Post-thaw viable CD45þ 2  107/kg 1.9 1.07-3.3 .01
Post-thaw viable CD34þ 1  105/kg 1.2 1.09-1.4 .01
ECLONE 20% 1.7 1.2-2.9 .005
Recipient CMV negative status 1.31 1.19-2.03 .02
Platelet engraftment
Post-thaw viable CD45þ 2  107/kg 1.19 1.08-1.33 .01
ECLONE 20% 1.53 1.09-2.1 .01
Recipient CMV status negative 1.47 1.12-2.22 .02
NRM
Early disease status .37 .09-.7 .01
ECLONE 20% .68 .38-.8 .02
Relapse risk
Advanced disease status 1.9 1.6-2.7 .02
Age 1.1 1.07-1.3 .01
DFS
Early disease status 1.9 1.1-3.5 .02
Post-thaw viable CD45þ 2  107/kg 2 1.4-2.7 .01
OS
Early disease status 1.8 1.1-3.5 .02
Post-thaw viable CD45þ 2  107/kg 2.1 1.4-2.7 .02
HR indicates hazard ratio.
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thaw vCD45þ was > or <2  107/kg were 21 (range, 9 to 49)
and 25 (range, 8 to 50) days, respectively. When ECLONE was
above the median (20%), the medians of neutrophil
engraftment were 22 (range, 8 to 49) and 26 (range, 17 to 51)
days, respectively. Among patients who presented primary
graft failure, 9 (82%) of them showed vCD45þ <2  107/kg
and 8 (73%) showed ECLONE < 20%. In these patients, the
median vCD45þ and ECLONE values were 1.65  107/kg
(range, .9 to 2.12) and 12% (range, 4 to 57), respectively.
Platelet engraftment
Platelet recovery was achieved in 90 patients at a median
of 36 days after UCB transplantation (range, 11 to 131). The
cumulative incidence of platelet engraftment at 120 dayswas
76% (95% CI, 68% to 86%). Multivariate analysis indicated that
a higher post-thaw vCD45þ cells (P ¼ .01), a higher ECLONE
(P ¼ .01), and recipient CMV negative status (P ¼ .02) were
independently associated with improved cumulative inci-
dence of platelet recovery. The impact of vCD45þ cells and
ECLONE on platelet engraftment is drawn in Figures 2A
and 2B.Figure 1. Unadjusted cumulative incidence of neutrophil engraftment according to
patients who received CBU with post-thaw vCD45þ above and below 2  107/kg, the
were 82% and 21 days and 67% and 25 days, respectively (P ¼ .003). For patients who
60 days and the median time to neutrophil recovery were 82% and 22 days and 80%NRM and relapse risk
After a median follow-up of 49 months (range, 12 to 114),
63 (57%) patients died, 47 (43%) of them from transplantation-
related causes. The cumulative incidence at 5 years of NRM
was 39% (95% CI, 29% to 49%). Multivariate analysis showed
that early disease status (P ¼ .01) and a higher value ECLONE
threshold (P ¼ .02) were associated with a lower NRM. The
effect of ECLONE on NRM is shown in Figure 3A. Sixteen pa-
tients relapsed after UCB transplantation, with a cumulative
incidence of relapse at 5 years of 19% (95% CI, 12% to 28%). The
5-year cumulative incidence of relapse risk was higher in
patients in advanced disease status (P ¼ .02) and in older
patients (P ¼ .01).
DFS and OS
The 5-year DFS and OS of the whole cohort were 40% (95%
CI, 31% to 51%) and 41% (95% CI, 32% to 52%), respectively. In
multivariate analysis, variables associated with improved
DFS and OS were a higher number of post-thaw vCD45þ cell
dose (P ¼ .01) and early disease status (P ¼ .02 and P ¼ .02).
The effect of post-thaw vCD45þ cell dose on DFS and OS is
represented in Figures 3B and 3C.DISCUSSION
This study highlights the ability of qualitative variables,
in particular vCD45þ cell dose and ECLONE, to predict
engraftment and NRM after myeloablative single UCBT in
adult patients with malignant diseases. Additionally, vCD45þ
events also correlated with DFS and OS.
Main factors to ensure engraftment after UCBT are the use
of well-matched HLA and high cell dose CBUs [1-3,7,22].
Nevertheless, despite the use of an adequate cell dose,
delayed engraftment or graft failure still remain concerns in
many UCBT series. Thus, the possibility arises that engraft-
ment may be inﬂuenced by additional quality factors.
Relevance of qualitative factors could derive from the fact
that cord blood undergoes several processing steps at
different times from collection to cryopreservation that can
trigger cell death by apoptosis [15]. With the current
methods used in clinical practice for determining cell
viability, apoptosis is not well assessed and ECLONE could be
more speciﬁc for this purpose.
Interestingly, in our study, post-thaw vCD45þ cell dose
appears to be a better predictor than TNCs of most important
transplantation outcomes. First, post-thaw vCD45þ cell dosepost-thaw vCD45þ  107/kg (A) and according to ECLONE threshold (B). For
cumulative incidence at 60 days and the median time to neutrophil recovery
received CBU with ECLONE above and below 20%, the cumulative incidence at
and 26 days, respectively (P < .001).
Figure 2. Unadjusted cumulative incidence of platelet engraftment according to post-thaw vCD45þ  107 per kg (A) and according to ECLONE threshold (B). For
patients who received CBU with vCD45þ above and below 2  107/kg, the cumulative incidence at 60 days and the median time to platelet recovery were 82% and
34 day and 76% and 36 days, respectively (P ¼ .08). For patients who received CBU with ECLONE above and below 20%, the cumulative incidence of platelet recovery at
60 days and the median time to platelet recovery were 86% and 32 days and 78% and 37 days, respectively (P < .001).
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engraftment. Assessment of vCD45þ cell dose at the time of
infusion can help to establish the quality status of CBUs as
cord blood manufacturing combines multiple processing
steps and prolonged time from collection to cryopreserva-
tion that might result in decreased CD45þ cells viability after
thawing. Further, we observed a favorable effect of post-thaw
vCD45þ cell dose on DFS and OS, compared with that of
TNCs.
The impact of post-thaw vCD45þ cell dose on the
outcome after UCBT has not been widely studied. Barlogis
et al. [23] reported an improvement of lymphocyte subset
reconstitution in children after UCBT receiving a higher post-
thaw vCD45þ cell dose/kg threshold than collected or
infused TNC and CD34þ cells. The hypotheses to explain this
observation is that TNC counts include other cells, such as
nonviable cells and mature erythroblasts, that are not
involved in engraftment. To the contrary, vCD45þ may
represent the group of cells actually delivering the biological
function such as lymphocytes, monocytes, and other acces-
sory cells contained in CBUs. The effect of non-HPC in CB
engraftment has been proposed by other groups, suggesting
the role of speciﬁc subsets, such as infused CD8þ in clinical
outcomes after UCBT [24].
Contrary to data from other groups, our data support the
value of CD34þ as a signiﬁcant factor affecting engraftment
[3,25], although interestingly, we found a statistically sig-
niﬁcant association between post-thaw vCD34þ and myeloidFigure 3. Unadjusted cumulative incidence of NRM (A). For patients who received CBU
and 5 years were 20%, 24%, and 30% whereas it was 24%, 38%, and 42% for the thres
vCD45þ cell dose above and below 2  107/kg were 42% and 41%, respectively, compa
post-thaw vCD45þ cell dose (P ¼ .03 and P ¼ .04 respectively).engraftment but neither total prefreezing nor total infused
CD34þ cell counts were predictive. These data reinforce the
importance of determining quality variables on CBUs and the
use of viable cell dose to better assess the potency. Consid-
ering the latter, our data are in accordance with other studies
that explored the role of post-thaw CD34þ cells viability,
concluding that CBUs with poor viability were unlikely to
engraft [12].
Page et al. [25] and other groups reported infused CFUs
dose over TNCs or CD34þ cells as the best predictive factor of
outcomes after transplantation [4,26]. Unlike these studies,
our results did not ﬁnd an association between total CFUs
infused and results after UCBT. It is likely that the use of a
high cut-off number of CD34þ for CBU selection minimizes
this factor. Noteably, our study reveals that ECLONE is an
independent factor on early outcome after UCBT because of
its association with neutrophil, platelet engraftment, and
NRM, adding a relevant role for a qualitative assessment of
clonogenic assays. We previously hypothesized that a
decrease in ECLONE can predict relevant losses in HPC
functionality [6] but its role has never been explored in a
patient cohort. Our study suggests that ECLONE may be a
dynamic surrogate of potency, revealing the apoptotic status
of CBUs. A potential application of this ﬁnding is the
assessment of ECLONE for CB selection, providing CD34þ
cells and CFU contents are currently required by interna-
tional CBB standards (ie, FACT-NETCORD) and is widely
available. Rodriguez et al. and others [27,28] suggested thatwith ECLONE above 20% the cumulative incidences of NRM at 100 days, 1 year,
hold below 20% (P ¼ .03). DFS and OS (B and C) for patients with postethaw
red with 25% and 24%, respectively, for patients who received a lower dose of
N. Castillo et al. / Biol Blood Marrow Transplant 21 (2015) 2167e21722172potency of CBUs can be tested in a contiguous segment to
establish the quality before release of the CBUs because of
the high correlation with the bag. In this sense, if the
contiguous segments are predictive of graft quality, ECLONE
value could be anticipated to identify CBUs with a decreased
probability of delayed engraftment or graft failure.
To our knowledge, this is the ﬁrst evidence that post-thaw
vCD45þ cell dose is associated either with main early and
long-term outcomes after UCBTand this study also shows the
importance of assessing CFUs not exclusively quantitatively
but with referral to the clonogenic potential of CD34þ cells in
the graft. Taking into account our results, we emphasize the
importance of the use of these variables, and we recommend
that they are added to the current CBU selection criteria.
There are not good assays for quality control of laboratories
for graft potency; however, this study suggests the use
by CBB of these simple assays (CD45þ viability and ECLONE)
to asses cord blood function using a validated contiguous
segment. These data can be used to predict potential prob-
lems in the CBU and to prevent using a suboptimal units.
Nevertheless, it should be noted that despite including pa-
tients receiving a relatively homogeneous conditioning
regimen and supportive care, this study presents limitations
because of the heterogeneous baseline diseases affecting the
patients and its limited sample size.
In conclusion, this study demonstrates that early and
long-term outcomes after single UCBT in adults with he-
matological malignancies improves when CBUs contain a
higher amount of post-thaw vCD45þ cell dose and a higher
ECLONE value, suggesting their clinical implications.
Furthermore, the assessment of these variables should be
considered and may be assessed in a representative refer-
ence sample in the routine selection strategies both at the
CBB and at transplantation centers.
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